Plasmodium yoelii nigeriensis (MDR)-efficacy of oral pyronaridine against multidrug-resistant malaria in Swiss mice.

Abstract

A multidrug-resistant strain of Plasmodium yoelii nigeriensis (MDR) showing a wide spectrum of resistance to chloroquine, amodiaquine, mepacrine, mefloquine, halofantrine, quinine, and quinidine was used in this study for in vivo evaluation of the blood schizontocidal activity of pyronaridine, a topoisomerase II inhibitor, in Swiss mice. The parasite produces 100% lethal infection in mice. The drug was administered orally once a day from day 0 onward. The initial studies showed that low doses of pyronaridine (0.625 to 5.0 mg base/kg x9 days) did not completely control blood-induced P. yoelii nigeriensis infection. Finally a series of doses of pyronaridine ranging from 1.25 to 30.0 mg/kg administered orally for 7 consecutive days were evaluated and in spite of high level of resistance to standard antimalarials, the parasite P. yoelii nigeriensis has shown complete susceptibility to pyronaridine (15 mg/kg dose x7 days). The present paper also compares the merits of a single MDR strain vs a battery of different resistant lines for quick antimalarials screening.

• Authors: R Tripathi, A Umesh, M Mishra, S K Puri, G P Dutta
• Journal: Experimental parasitology (Exp Parasitol) Vol. 94 Issue 3 Pg. 190-3 (Mar 2000) ISSN: 0014-4894 [Print] United States
• PMID: 10831384 (Publication Type: Journal Article)
• Copyright: Copyright 2000 Academic Press.

Chemical References

• Antimalarials
• Naphthyridines
• Topoisomerase II Inhibitors
• pyronaridine

Topics

• Animals
• Antimalarials (pharmacology, therapeutic use)
• Drug Resistance, Multiple
• Malaria (drug therapy, parasitology)
• Mice
• Naphthyridines (pharmacology, therapeutic use)
• Plasmodium yoelii (drug effects)
• Topoisomerase II Inhibitors